 | |
| Combination of | |
|---|---|
| Olanzapine | Atypical antipsychotic |
| Fluoxetine | Selective serotonin reuptake inhibitor |
| Clinical data | |
| Trade names | Symbyax, Cinol Forte, Olapin Forte, others |
| AHFS/Drugs.com | Professional Drug Facts |
| License data | |
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| KEGG | |
  (what is this?) (verify) | |
Olanzapine/fluoxetine (trade name Symbyax, created by Eli Lilly and Company) is a fixed-dose combination medication containing olanzapine (Zyprexa), an atypical antipsychotic, and fluoxetine (Prozac), a selective serotonin reuptake inhibitor (SSRI). Olanzapine/fluoxetine is primarily used to treat the depressive episodes of bipolar I disorder[2] as well as treatment-resistant depression.[1][3]
- ^ a b "Symbyax- olanzapine and fluoxetine hydrochloride capsule". DailyMed. 21 April 2020. Retrieved 30 September 2020.
- ^ "Tratamento medicamentoso dos transtornos bipolares - Transtornos psiquiátricos". Manuais MSD edição para profissionais (in Brazilian Portuguese). Retrieved 2022-10-02.
- ^ Benazzi F, Berk M, Frye MA, Wang W, Barraco A, Tohen M (October 2009). "Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis". The Journal of Clinical Psychiatry. 70 (10): 1424–1431. doi:10.4088/JCP.08m04772gre. PMID 19906346.